Alzheimer’s Disease is the most common type of dementia, a condition manifested when nerve cells in the brain (neurons) die or no longer function normally. This causes changes in memory, behavior, the ability to perform day-to-day activities and cognitive function. When dementia is caused by Alzheimer’s Disease, these brain changes eventually impair the ability to carry out the most basic bodily functions, such as walking and swallowing. Alzheimer’s Disease is ultimately fatal.
Alzheimer’s Disease is the sixth leading cause of death in the U.S., and the fifth leading cause of death for people age 65 and older. It is the only disease, out of the 10 diseases with the highest mortality rates in the U.S., that cannot be prevented, cured or modified. Moreover, there are no methods to reduce prevalence.
Beyond the great emotional stress the disease causes, as the longevity of the general population extends, the financial burden continues to soar. The costs of caring for Alzheimer’s patients are expected to increase from an estimated $200 billion in 2013 to a projected $1.200 trillion annually by 2050.
None of the pharmacologic treatments available today for Alzheimer’s Disease can actually slow or stop the malfunction and death of neurons in the brain that cause Alzheimer’s symptoms – and ultimately make the disease fatal. There are five drugs approved by the U.S. Food and Drug Administration that have shown to deliver a degree of temporary improvement in symptoms. They work by increasing the amount of chemicals called neurotransmitters in the brain. The effectiveness of these drugs varies across the population, and at best, has shown to only delay worsening symptoms by several months.
Alzheimer’s Association, 2016 Alzheimer’s Disease Facts and Figures, Alzheimer’s & Dementia, Volume 9, Issue 2
neuroAD is an investigational device currently not commercially available in the United States.
neuroAD is CE-cleared and commercially available for the treatment of mild to moderate Alzheimer’s Disease in Europe.